GSK, Novartis Downplay Pfizer/Pharmacia: New Themes For “Critical Mass”?
Executive Summary
The Pfizer/Pharmacia merger will not fundamentally change the pharmaceutical industry dynamics unless Pfizer sheds product lines to concentrate greater resources behind key brands, Novartis and GSK argued in separate investor presentations
You may also be interested in...
Pfizer/Pharmacia Flexes Market Strength: More Bulk For Medicaid/Medicare
Pfizer's $60 bil. stock acquisition of Pharmacia would create a combined company with over $23 bil. in annual U.S. drug sales with commensurate influence and bargaining power with large Rx drug purchasers
Novartis Merger Stance: Firm "Prefers" No Deal For At Least Two Years
Novartis would "prefer" to wait two or three years before its next large transaction so it can focus on upcoming product launches, CFO Raymund Breu told the J.P. Morgan CEO conference on building shareholder value April 26.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011